MAXWELL; Brad D.

Patent Applications and Registrations

Patent applications and USPTO patent grants for MAXWELL; Brad D..The latest application filed is for "inhibitors of apol1 and methods of using same".

Company Profile

4.5.7

MAXWELL; Brad D. - Holliston MA
Maxwell; Brad D. - Doylestown PA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Inhibitors Of Apol1 And Methods Of Using Same App 20220106327 - AHN; Jun Myun ; et al.	2022-04-07
Modulators Of Alpha-1 Antitrypsin App 20210179587 - BANDARAGE; Upul Keerthi ; et al.	2021-06-17
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation Grant 10,822,343 - Banville , et al. November 3, 2	2020-11-03
Imidazothiadiazole And Imidazopyrazine Derivatives As Protease Activated Receptor4 (par4) Inhibitors For Treating Platelet Aggre App 20200123160 - Banville; Jacques ; et al.	2020-04-23
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation Grant 10,428,077 - Banville , et al. October 1, 2	2019-10-01
Imidazothiadiazole And Imidazopyrazine Derivatives As Protease Activated Receptor4 (par4) Inhibitors For Treating Platelet Aggregation App 20180305376 - Banville; Jacques ; et al.	2018-10-25
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation Grant 10,047,103 - Banville , et al. August 14, 2	2018-08-14
Imidazothiadiazole And Imidazopyrazine Derivatives As Protease Activated Receptor4 (par4) Inhibitors For Treating Platelet Aggregation App 20170247395 - Banville; Jaques ; et al.	2017-08-31
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation Grant 9,688,695 - Banville , et al. June 27, 2	2017-06-27
Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors Grant 9,580,422 - Cheng , et al. February 28, 2	2017-02-28
Isotopically Labeled Triazolopyridine 11-beta Hydroxysteroid Dehydrogenase Type I Inhibitors App 20160257680 - Cheng; Yaofeng ; et al.	2016-09-08
Imidazothiadiazole And Imidazopyrazine Derivatives As Protease Activated Receptor 4 (par4) Inhibitors For Treating Platelet Aggregation App 20150094297 - Banville; Jacques ; et al.	2015-04-02

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.